Senior Director, Vonjo, Core Asset Team; CAT) Lead

Company Description

At Sobi, we believe diversity drives innovation and inclusion creates stronger teams. We are committed to building a workplace where everyone feels valued and empowered to contribute.

At Sobi, each person brings their unique talents to work as a team and make a difference. We are dedicated to developing and delivering innovative therapies to improve the lives of people who live with a rare disease. Our edge comes from our team of people and our commitment to patients.

Our mission and culture at Sobi North America get us excited to come to work every day, but here are a few more reasons to join our team:

• Competitive compensation for your work
• Generous time off policy
• Opportunity to broaden your horizons by attending popular conferences
• Emphasis on work/life balance
• Collaborative and team-oriented environment
• Making a positive impact to help ultra-rare disease patients who are in need of life saving treatments

The Vonjo Core Asset Team (CAT) Lead is a senior cross-functional lead accountable for defining and executing the global strategy for Sobi's Vonjo portfolio, including its established myelofibrosis indication and pipeline expansion opportunities. This includes label expansion in myelofibrosis, development of a new indication and global program for VEXAS, lifecycle management (LCM), regulatory and commercial readiness, and long-term value maximization across key global markets - with the U.S. as the lead focus.

The role orchestrates an integrated strategy and execution plan to ensure successful development, approval, geographic expansion, and sustained global growth of Sobi's Vonjo asset.

Reports to: Vice President, US Hematology

• Define and lead the global asset strategy for Vonjo, aligned with corporate priorities, spanning myelofibrosis label expansion and the emerging VEXAS indication.
• Develop and maintain a high-quality Integrated Project Plan (IPP), including resourcing and budget.
• Drive lifecycle management (LCM) to extend product value and optimize portfolio performance, with a focus on broader label and indication expansion opportunities beyond current approved use.
• Lead the strategic development of the new VEXAS indication, including shaping the global program architecture from early planning through regulatory submission and launch.
• Ensure readiness of global regulatory submissions and approvals for myelofibrosis label expansion and VEXAS indication.
• Align evidence generation plans with asset strategy, guiding clinical, medical, and real-world data priorities to support label expansion and indication expansion efforts.
• Assess ex-U.S. markets to identify viable pathways and develop focused geographic expansion plans, building a truly global footprint for Vonjo.
• Engage and build relationships, in coordination with Medical, with select top-tier KOLs to inform the strategy.

• Lead and develop the Core Asset Team (CAT), integrating expertise from R&D, Medical Affairs, Tech Ops, Commercial, and Project Management.
• Partner closely with regional and functional leaders to align global strategy with local execution.
• Ensure effective coordination between CAT members and their respective functional asset teams to execute functional plans.
• Collaborate closely with executive leadership and cross-functional teams across R&D, Medical Affairs, Market Access, Regulatory, Tech Ops, and Commercial to ensure strategic alignment and execution.

• Build the investment cases and ensure budgets remain within approved guardrails.
• Coordinate and oversee CAT members' strategy execution, leveraging functional expertise.
• Prepare for and represent the asset in ExCom Portfolio Reviews and…